A Phase 2 interventional study of Futibatinib and Futibatinib plus Fulvestrant in Metastatic Breast Cancer, FGFR 1 High Amplification and FGFR2 Amplification, sponsored by Taiho Oncology, Inc.. Terminated at 37 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-13.
Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 49th largest by enrollment of the 94 interventional ones that give a count, is one of 4 that started in 2020, is one of 59 in phase 2, and was the 71st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taiho Oncology, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
Otsuka Holdings Co., Ltd. has 9 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.
This is a Phase 2, open-label, non-randomized, multicenter study designed to evaluate the efficacy and safety of futibatinib (TAS-120) and futibatinib + fulvestrant in up to 168 adult patients with locally advanced/metastatic breast cancer harboring FGFR gene amplifications. Patients will be enrolled to 1 of 4 treatment cohorts based on diagnosis and FGFR gene amplification status, and will receive either single agent futibatinib in Cohorts 1-3 or futibatinib plus fulvestrant in Cohort 4, as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed recurrent locally advanced or breast cancer not amenable to treatment with curative intent, and the following cohort specific criteria:
A. Cohort 1
B. Cohort 2
C. Cohort 3
D. Cohort 4
Exclusion Criteria:
History and/or current evidence of any of the following disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced or metastatic hormone receptor - positive (HR+), human epidermal growth factor receptor 2 - negative (HER2-) breast cancer, harboring fibroblast growth factor receptor 2 (FGFR2) gene amplification, with measurable disease received futibatinib, 20 milligrams (mg), oral tablets, once daily for a continuous 28-day cycle up to maximum of 244 days.
Drug: Futibatinib
Participants with advanced or metastatic triple negative breast cancer (TNBC), harboring FGFR2 gene amplification, with measurable disease received futibatinib, 20 mg, oral tablets, once daily for a continuous 28-day cycle up to maximum of 1066 days.
Drug: Futibatinib
Participants with advanced or metastatic HR+, HER2- or TNBC, harboring FGFR2 gene amplification, with non-measurable disease received futibatinib, 20 mg, oral tablets, once daily for a continuous 28-day cycle up to maximum of 252 days.
Drug: Futibatinib
Participants with advanced or metastatic HR+ HER2- breast cancer, harboring FGFR1 gene amplification, with measurable disease, received futibatinib, 20 mg, oral tablets, once daily for a continuous 28-day cycle up to maximum of 645 days. They also received intramuscular (IM) fulvestrant 500 mg on Days 1 and 15 of Cycle 1 and Day 1 of every subsequent cycle up to maximum of 618 days.
Drug: Futibatinib plus Fulvestrant
Futibatinib 20mg once daily on a 28-day cycle
Also known as: TAS-120
Drug pages: Futibatinib · Fulvestrant
Futibatinib 20mg once daily on a 28-day cycle and fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.
Objective Response Rate (ORR) - Cohorts 1, 2
ORR was defined as the percentage of participants with a confirmed response of either complete response (CR) or partial response (PR), based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (up to 40 months)
Clinical Benefit Rate (CBR) - Cohort 3
CBR was defined as the percentage of participants with a confirmed response of CR or stable disease (SD) lasting at least 24 weeks, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10mm. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicates progression. Percentages were rounded off to the nearest
Time frame: At the end of every 2 cycles until disease progression (up to 40 months)
6-month Progression-free Survival (PFS) Rate - Cohort 4
The 6-month PFS rate was defined as the percentage of participants who are alive and progression-free 6 months after the first dose of study drug. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (up to 6 months)
Complete Response (CR) Rate - Cohort 3
CR rate was defined as the percentage of participants who achieved CR. CR was defined as disappearance of all targets. Any pathological lymph node must have reduction in short axis to \<10 mm. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (up to 40 months)
Overall Response Rate (ORR) - Cohort 4
ORR was defined as the percentage of participants with a confirmed response of either CR or PR, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (up to 40 months)
Clinical Benefit Rate (CBR) - Cohort 1,2, and 4
CBR was defined as the percentage of participants with a confirmed response of CR, PR or SD lasting at least 24 weeks, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicates progression. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (up to 40 months)
6-month PFS Rate - Cohorts 1,2, and 3
The 6-month PFS rate was defined as the percentage of participants who are alive and progression-free 6 months after the first dose of study drug. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (up to 6 months)
Progression Free Survival (PFS)
PFS was defined as the time from the first dose of study therapy to the date of death (any cause) or disease progression based on investigator assessment, whichever occurs first. The PFS was analyzed using a Kaplan-Meier method with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.
Time frame: At the end of every 2 cycles until disease progression (up to 40 months)
Duration of Response (DOR)
DOR was defined as the time from the first documentation of objective response to the to the date of death (any cause) or disease progression, based on Investigator assessment, whichever occurs first. Objective response was defined as participants with a confirmed response of either CR or PR, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.
Time frame: At the end of every 2 cycles until disease progression (up to 40 months)
Overall Survival (OS)
OS was defined as the time (in months) from the date of first dose of the study drug to the date of death. Participants without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 95% CI for median OS was provided using the Kaplan-Meier procedure.
Time frame: Up to 40 months
Number of Participants With Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug.
Time frame: From the first dose of study drug up to 30 days after the last dose (Up to 40 months)
Number of Participants With Dose Limiting Toxicities (DLTs) - Cohort 4
A DLT was defined as any AE that occurs during Cycle 1 that is not clearly attributable to an extraneous cause, such as an underlying disease, occurring in Cycle 1, and meeting at least one of the criteria defined in the protocol. An AE is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug.
Time frame: Cycle 1 (cycle length= 28 days)
Participants took part in the study from 28 January 2020 to 06 September 2023.
| Milestone | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|---|---|---|
| Started | 17 | 21 | 4 | 22 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 17 | 21 | 4 | 22 |
| Withdrew: Death | 10 | 14 | 2 | 7 |
| Withdrew: Loss to follow up | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal of consent | 2 | 0 | 0 | 1 |
| Withdrew: Study termination by sponsor | 4 | 6 | 2 | 11 |
| Withdrew: Reason not specified | 0 | 1 | 0 | 2 |
ORR was defined as the percentage of participants with a confirmed response of either complete response (CR) or partial response (PR), based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) |
|---|---|---|
| Objective Response Rate (ORR) - Cohorts 1, 2 | 0 (0.0 to 19.5) | 9.5 (1.2 to 30.4) |
CBR was defined as the percentage of participants with a confirmed response of CR or stable disease (SD) lasting at least 24 weeks, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10mm. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicates progression. Percentages were rounded off to the nearest
| percentage of participants | Futibatinib (Cohort 3) |
|---|---|
| Clinical Benefit Rate (CBR) - Cohort 3 | 50.0 (6.8 to 93.2) |
The 6-month PFS rate was defined as the percentage of participants who are alive and progression-free 6 months after the first dose of study drug. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|
| 6-month Progression-free Survival (PFS) Rate - Cohort 4 | 45.5 (24.4 to 67.8) |
CR rate was defined as the percentage of participants who achieved CR. CR was defined as disappearance of all targets. Any pathological lymph node must have reduction in short axis to \<10 mm. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib (Cohort 3) |
|---|---|
| Complete Response (CR) Rate - Cohort 3 | 0 (0.0 to 60.2) |
ORR was defined as the percentage of participants with a confirmed response of either CR or PR, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|
| Overall Response Rate (ORR) - Cohort 4 | 18.2 (5.2 to 40.3) |
CBR was defined as the percentage of participants with a confirmed response of CR, PR or SD lasting at least 24 weeks, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicates progression. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|---|---|
| Clinical Benefit Rate (CBR) - Cohort 1,2, and 4 | 11.8 (1.5 to 36.4) | 23.8 (8.2 to 47.2) | 50.0 (28.2 to 71.8) |
The 6-month PFS rate was defined as the percentage of participants who are alive and progression-free 6 months after the first dose of study drug. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) |
|---|---|---|---|
| 6-month PFS Rate - Cohorts 1,2, and 3 | 5.9 (0.1 to 28.7) | 19.0 (5.4 to 41.9) | 50.0 (6.8 to 93.2) |
PFS was defined as the time from the first dose of study therapy to the date of death (any cause) or disease progression based on investigator assessment, whichever occurs first. The PFS was analyzed using a Kaplan-Meier method with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.
| months | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 3.7 (1.7 to 5.1) | 1.9 (1.6 to 4.0) | 12.4 (1.9 to NA) | 7.2 (2.1 to 7.6) |
DOR was defined as the time from the first documentation of objective response to the to the date of death (any cause) or disease progression, based on Investigator assessment, whichever occurs first. Objective response was defined as participants with a confirmed response of either CR or PR, based on Investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.
| months | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|---|---|---|
| Duration of Response (DOR) | — | 3.38 (3.1 to 3.7) | — | 6.34 (3.3 to 16.7) |
OS was defined as the time (in months) from the date of first dose of the study drug to the date of death. Participants without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 95% CI for median OS was provided using the Kaplan-Meier procedure.
| months | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|---|---|---|
| Overall Survival (OS) | 16.5 (8.1 to NA) | 10.2 (6.1 to 21.8) | 30.4 (12.4 to NA) | 23.9 (20.6 to NA) |
An AE is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug.
| Participants | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 17 | 21 | 4 | 22 |
A DLT was defined as any AE that occurs during Cycle 1 that is not clearly attributable to an extraneous cause, such as an underlying disease, occurring in Cycle 1, and meeting at least one of the criteria defined in the protocol. An AE is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug.
| Participants | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) - Cohort 4 | 0 |
Collected over From the first dose of study drug up to 30 days after the last dose (Up to 40 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Futibatinib (Cohort 1) | 10/17 (58.8%) | 4/17 (23.5%) | 16/17 (94.1%) |
| Futibatinib (Cohort 2) | 14/21 (66.7%) | 5/21 (23.8%) | 21/21 (100%) |
| Futibatinib (Cohort 3) | 2/4 (50%) | 1/4 (25%) | 4/4 (100%) |
| Futibatinib Plus Fulvestrant (Cohort 4) | 7/22 (31.8%) | 4/22 (18.2%) | 22/22 (100%) |
| Event | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|---|---|---|
| Pathological fractureMusculoskeletal and connective tissue disorders | 0/17 | 0/21 | 1/4 | 0/22 |
| NauseaGastrointestinal disorders | 1/17 | 0/21 | 0/4 | 0/22 |
| COVID-19Infections and infestations | 1/17 | 0/21 | 0/4 | 0/22 |
| HyperphosphataemiaMetabolism and nutrition disorders | 1/17 | 0/21 | 0/4 | 0/22 |
| Acute promyelocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/17 | 0/21 | 0/4 | 0/22 |
| Acute kidney injuryRenal and urinary disorders | 1/17 | 1/21 | 0/4 | 0/22 |
| InfluenzaInfections and infestations | 0/17 | 1/21 | 0/4 | 0/22 |
| Urinary tract infectionInfections and infestations | 0/17 | 1/21 | 0/4 | 0/22 |
| Urinary tract obstructionRenal and urinary disorders | 0/17 | 1/21 | 0/4 | 0/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/17 | 1/21 | 0/4 | 0/22 |
| Event | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) |
|---|---|---|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 13/17 | 18/21 | 3/4 | 21/22 |
| FatigueGeneral disorders | 4/17 | 7/21 | 3/4 | 7/22 |
| ConstipationGastrointestinal disorders | 8/17 | 9/21 | 1/4 | 13/22 |
| Alanine aminotransferase increasedInvestigations | 4/17 | 2/21 | 0/4 | 13/22 |
| AlopeciaSkin and subcutaneous tissue disorders | 4/17 | 3/21 | 1/4 | 13/22 |
| Aspartate aminotransferase increasedInvestigations | 7/17 | 5/21 | 0/4 | 11/22 |
| PruritusSkin and subcutaneous tissue disorders | 3/17 | 1/21 | 2/4 | 1/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/17 | 4/21 | 2/4 | 7/22 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/17 | 3/21 | 2/4 | 3/22 |
| DysgeusiaNervous system disorders | 1/17 | 0/21 | 2/4 | 5/22 |
All treated population included all enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) | Total |
|---|---|---|---|---|---|
| Mean | 59.8 ± 11.42 | 51.4 ± 14.50 | 60.8 ± 5.74 | 52.7 ± 12.68 | 54.7 ± 13.01 |
| Sex: Female, Male(Participants) | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) | Total |
|---|---|---|---|---|---|
| Female | 17 | 21 | 4 | 22 | 64 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 | 4 |
| Not Hispanic or Latino | 15 | 15 | 4 | 13 | 47 |
| Unknown or Not Reported | 1 | 5 | 0 | 7 | 13 |
| Race (NIH/OMB)(Participants) | Futibatinib (Cohort 1) | Futibatinib (Cohort 2) | Futibatinib (Cohort 3) | Futibatinib Plus Fulvestrant (Cohort 4) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 2 | 1 | 0 | 1 | 4 |
| White | 14 | 12 | 4 | 16 | 46 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 7 | 0 | 4 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in May 2023, 40 months.
Results were first posted in Nov 2025, 2 years 5 months after primary completion. A results delay was requested in May 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Futibatinib · Fulvestrant